Abstract
Context: Improved biomarkers would facilitate the diagnosis and treatment of autism spectrum disorders (ASD).
Objective: Our objective was to examine the levels of Nogo-A and glial fibrillary acidic protein (GFAP) in children with ASD.
Materials and methods: Serum concentrations of GFAP and Nogo-A were determined by enzyme-linked immunosorbent assay.
Results: In this preliminary study, we found that serum Nogo-A was not found significantly different between groups, while serum levels of GFAP were significantly lower in ASD than controls.
Discussion and conclusions: It will be of great interest to determine other potential causes of elevated serum levels of GFAP, and whether this elevation has any phenotypic effect.
Acknowledgements
We thank Nurse Selma Şenlikçi Kaçar and Nur Hanim for their excellent technical assistance and participants.
Disclosure statement
The authors report no declarations of interest.
Funding information
This research work was supported by Grants from Batman University Scientific Research Project Coordination Center (BTUBAP-2014-YL1).